Skip to main content

Theratechnologies Announces Special Shareholder Meeting for September 2025

Tipranks - Sat Jul 19, 2025

Elevate Your Investing Strategy:

Theratechnologies ( (TSE:TH) ) just unveiled an update.

Theratechnologies Inc. announced a special meeting of shareholders scheduled for September 12, 2025, with a record date for notice and voting set for August 13, 2025. This meeting, which will be held in a hybrid format, is significant for stakeholders as it may impact the company’s strategic direction and governance.

The most recent analyst rating on (TSE:TH) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Theratechnologies stock, see the TSE:TH Stock Forecast page.

Spark’s Take on TSE:TH Stock

According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.

Theratechnologies shows strong technical momentum and positive strategic developments, including an acquisition agreement. However, significant financial challenges and valuation concerns limit the overall score. The company’s ability to execute on strategic initiatives and improve its financial health will be crucial for future performance.

To see Spark’s full report on TSE:TH stock, click here.

More about Theratechnologies

Theratechnologies Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company primarily targets unmet medical needs in the fields of HIV and oncology.

Average Trading Volume: 80,412

Technical Sentiment Signal: Hold

Current Market Cap: C$197.7M

See more insights into TH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.